No information is available on the use of venetoclax during breastfeeding. Because venetoclax is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 26 hours and it might accumulate in the infant. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] The manufacturer recommends that breastfeeding be discontinued during vemurafenib therapy and for 1 week after the final dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[3]
关于维奈托克在母乳喂养期间的使用尚无可用信息。由于维奈托克与血浆蛋白的结合率超过99%，乳汁中的含量可能较低。然而，其半衰期为26小时，可能会在婴儿体内蓄积。大多数资料认为，母亲接受抗肿瘤药物治疗期间禁忌母乳喂养。[1]制造商建议在维莫非尼治疗期间及最后一剂后1周内停止母乳喂养。化疗可能会对母乳的正常微生物群和化学成分产生不利影响。[2]孕期接受化疗的女性更有可能在哺乳婴儿时遇到困难。[3]
